Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Anything goes -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (17789)	5/14/1998 10:47:00 AM
From: Jack of All Trades	Read Replies (1) \| Respond to of 34592

HYALF news! biz.yahoo.com Thursday May 14, 10:17 am Eastern Time Company Press Release SOURCE: Hyal Pharmaceutical Corporation Hyal Appoints Two New Directors MISSISSAUGA, Ont., May 14 /CNW-PRN/ - Hyal Pharmaceutical Corporation (NASDAQ/NNM:HYALF - news; TSE:HPC - news) is pleased to announce the appointment of Dr. George A. deVeber and Dr. Jan Oudenes to the Board of Directors of the Corporation. Dr. deVeber is a prominent Canadian nephrologist and biotechnology consultant who initiated and led the Dialysis and Transplantation program at Toronto's Western Hospital. A well-known consultant in the areas of thcare, biotechnology and government affairs, he is currently the Medical Director of Vasogen, Inc. Dr. deVeber is a former Vice President, Medical Affairs of Baxter Corporation, and a past President of the Canadian Transplantation Society and the Ontario branch of the Kidney Foundation of Canada. Dr. Oudenes is a well-known scientist in the field of synthetic organic chemistry and pharmaceutical chemistry. For the past decade, he has been President of Torcan Chemical Ltd., a research, development and manufacturing company of new chemical entities and active pharmaceutical ingredients, based in Aurora, Ontario. Dr. Oudenes studied in The Netherlands, Canada and Switzerland, and has published extensively in scientific and patent literature. Hyal Pharmaceutical Corporation is a drug delivery company engaged in research and development and is seeking worldwide commercialization of pharmaceutical formulations utilizing its proprietary Hyaluronan Induced Targeting Technology (HIT)(TM) and Hyaluronan Improved Liposome Technology (HILT)(TM). SOURCE: Hyal Pharmaceutical Corporation More Quotes and News: Hyal Pharmaceutical Corp (Toronto:HPC.TO - news; Toronto:HPC.TO - news; Nasdaq:HYALF - news) Related News Categories: medical/pharmaceutical